Beta%25252520blockers

# Beta Blockers ## Overview Beta-adrenergic blocking agents competitively antagonize catecholamines at beta-adrenergic receptors. They are categorized by selectivity (beta-1 cardioselective vs. non-selective) and intrinsic sympathomimetic activity (ISA). Common examples include metoprolol (selective), bisoprolol (selective), propranolol (non-selective), and carvedilol (non-selective with alpha-1 blockade). ## Primary Indications * Hypertension * Heart failure with reduced ejection fraction (HFrEF) * Post-myocardial infarction (MI) * Atrial fibrillation (rate control) * Angina pectoris * Essential tremor (propranolol) * Migraine prophylaxis (propranolol/metoprolol) ## Adult Dosing *Dosing varies significantly by agent and indication; follow institution-specific protocols.* * **Metoprolol Succinate (ER):** Start 25–50 mg daily; titrate every 2 weeks to target dose (max 200 mg/day). * **Carvedilol:** Start 3.125 mg BID; titrate every 2 weeks to target dose (max 25 mg BID for HFrEF, 50 mg BID for post-MI/HTN). * **Bisoprolol:** Start 1.25–2.5 mg daily; titrate every 2 weeks to target dose (max 10 mg/day). * **Propranolol (Immediate Release):** 40–160 mg/day in 2–4 divided doses for hypertension. ## Pediatric Dosing *Pediatric dosing is highly weight-based and specific to the indication; always consult a pediatric formulary (e.g., Harriet Lane).* * **Propranolol:** Hypertension: 0.5–1 mg/kg/day divided BID–QID (max 8 mg/kg/day). * **Atenolol:** Hypertension: 0.5–1 mg/kg/day (max 2 mg/kg/day). * **Metoprolol:** Hypertension: 1–2 mg/kg/day divided BID. ## Dose Adjustments * **Renal Impairment:** Generally unnecessary for lipophilic agents (metoprolol, propranolol). Atenolol and bisoprolol may require reduction in severe renal impairment (CrCl < 30 mL/min). * **Hepatic Impairment:** Lipophilic beta-blockers undergo extensive hepatic metabolism; dose reduction or slower titration is recommended. ## Contraindications * Second or third-degree heart block (without a pacemaker). * Sick sinus syndrome or severe bradycardia. * Decompensated heart failure (unless stable). * Severe reactive airway disease (asthma/COPD) for non-selective agents (e.g., propranolol). * Cardiogenic shock. ## Adverse Effects * Bradycardia and hypotension. * Fatigue and exercise intolerance. * Masking of hypoglycemia symptoms (tachycardia/tremor). * Bronchospasm in sensitive patients. * Sexual dysfunction. * Cold extremities/Raynaud's phenomenon. ## Key Drug Interactions * **Non-dihydropyridine CCBs (Diltiazem/Verapamil):** Potentiation of bradycardia and AV block. * **CYP2D6 Inhibitors (e.g., Fluoxetine/Paroxetine):** Increases levels of metoprolol/carvedilol. * **Insulin/Sulfonylureas:** Masking of hypoglycemia and potentiation of hypoglycemic episodes. * **Digoxin:** Additive slowing of AV node conduction. ## Monitoring * **Baseline:** Heart rate, blood pressure, ECG (for conduction abnormalities). * **Ongoing:** Heart rate (titrate to resting HR > 55 bpm), BP, presence of peripheral edema/pulmonary congestion (for HFrEF), and blood glucose levels in diabetic patients. ## Clinical Pearls 1. **Do not discontinue abruptly:** Can trigger rebound hypertension or tachycardia; taper over 1–2 weeks. 2. **Cardioselectivity:** Selectivity is lost at higher doses (e.g., high-dose metoprolol may affect beta-2 receptors). 3. **Heart Failure:** Always initiate at very low doses in HF patients to avoid acute decompensation; titrate slowly. 4. **Monitoring:** Counsel patients that the masking effect on hypoglycemia refers to physical symptoms; sweating usually remains unchanged. *** **Disclaimer:** This information is for educational purposes only. Always consult current institutional protocols, clinical guidelines (e.g., ACC/AHA), and the specific drug package insert before prescribing or administering medication.